Statements of Operations (USD $)	12 Months Ended
	Dec. 31, 2013	Dec. 31, 2012
Product sales, net	$ 10,011,420	$ 8,648,242
Cost of products sold	3,198,908	3,055,991
Gross profit	6,812,512	5,592,251
Selling, general and administrative expenses	5,534,463	5,930,625
Research and development expenses	191,345	181,979
Total operating expenses	5,725,808	6,112,604
Income (loss) from operations	1,086,704	(520,353)
Other income (expense)
Other income	17,543
Interest income	115	34
Interest expense	(70,801)	(175,905)
Interest-Amortized debt issuance - cost	0.00	(3,065)
Loss on Earnings from Medical Joint Venture	(924,363)	(171,016)
Loss on Earnings from Education Joint Venture	(7,918)
Gain on Dilutive Effect on Medical Joint Venture stock issuance	1,363,650
Total other expense, net	378,226	(349,952)
Income (loss)	1,464,930	(870,306)
Provision for Income Tax
Net Income (loss)	$ 1,464,930	$ (870,306)
Net income (loss) per share applicable to common stockholders -
Basic	$ 0.09	$ (0.05)
Diluted	$ 0.08	$ (0.05)
Weighted average shares outstanding and to be issued -
Basic	17,127,468	16,080,474
Diluted	17,483,638	16,080,474